This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v1.5 was used to generate the results found in this report.
-
Working with individual set: KIRP-TP
-
Number of patients in set: 168
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:KIRP-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 13
-
Mutations seen in COSMIC: 91
-
Significantly mutated genes in COSMIC territory: 4
-
Significantly mutated genesets: 0
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 168 MAFs of type "Baylor-Illumina"
-
Total number of mutations in input MAFs: 34640
-
After removing 47 mutations outside chr1-24: 34593
-
After removing 795 blacklisted mutations: 33798
-
After removing 1228 noncoding mutations: 32570
-
After collapsing adjacent/redundant mutations: 32535
-
Number of mutations before filtering: 32535
-
After removing 1555 mutations outside gene set: 30980
-
After removing 43 mutations outside category set: 30937
-
After removing 1 "impossible" mutations in
-
gene-patient-category bins of zero coverage: 29338
type | count |
---|---|
Frame_Shift_Del | 913 |
Frame_Shift_Ins | 305 |
In_Frame_Del | 189 |
In_Frame_Ins | 48 |
Missense_Mutation | 19167 |
Nonsense_Mutation | 1446 |
Nonstop_Mutation | 1 |
Silent | 8159 |
Splice_Site | 709 |
Total | 30937 |
category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
---|---|---|---|---|---|---|
Cp*C->A | 9643 | 736603118 | 0.000013 | 13 | 2.9 | 2.4 |
(A/G/T)p*C->A | 2015 | 1855937043 | 1.1e-06 | 1.1 | 0.24 | 5.9 |
C->(T/G) | 3957 | 2592540161 | 1.5e-06 | 1.5 | 0.34 | 2.8 |
A->mut | 3550 | 2479040004 | 1.4e-06 | 1.4 | 0.32 | 3.9 |
indel+null | 3570 | 5071580165 | 7e-07 | 0.7 | 0.16 | NaN |
double_null | 42 | 5071580165 | 8.3e-09 | 0.0083 | 0.0018 | NaN |
Total | 22777 | 5071580165 | 4.5e-06 | 4.5 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom). If the figure is unpopulated, then full coverage is assumed (e.g. MutSig CV doesn't use WIGs and assumes full coverage).
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: Cp*C->A
-
n2 = number of nonsilent mutations of type: (A/G/T)p*C->A
-
n3 = number of nonsilent mutations of type: C->(T/G)
-
n4 = number of nonsilent mutations of type: A->mut
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NF2 | neurofibromin 2 (merlin) | 286910 | 12 | 12 | 12 | 1 | 3 | 0 | 0 | 0 | 9 | 0 | 0.35 | 3.6e-10 | 6.5e-06 |
2 | HNRNPM | heterogeneous nuclear ribonucleoprotein M | 335730 | 11 | 11 | 2 | 0 | 0 | 0 | 1 | 0 | 10 | 0 | 0.06 | 1.4e-09 | 0.000013 |
3 | MET | met proto-oncogene (hepatocyte growth factor receptor) | 720248 | 16 | 15 | 14 | 0 | 0 | 0 | 5 | 10 | 1 | 0 | 0.021 | 7.2e-09 | 0.000044 |
4 | BMS1 | BMS1 homolog, ribosome assembly protein (yeast) | 621296 | 14 | 13 | 5 | 1 | 13 | 1 | 0 | 0 | 0 | 0 | 0.16 | 6.5e-08 | 0.0003 |
5 | ZNF598 | zinc finger protein 598 | 334720 | 14 | 13 | 5 | 2 | 4 | 0 | 0 | 10 | 0 | 0 | 0.27 | 1.1e-07 | 0.0004 |
6 | NEFH | neurofilament, heavy polypeptide 200kDa | 364887 | 14 | 10 | 6 | 1 | 0 | 0 | 7 | 2 | 5 | 0 | 0.25 | 1.4e-07 | 0.00042 |
7 | ACTB | actin, beta | 188529 | 7 | 7 | 7 | 0 | 1 | 0 | 1 | 5 | 0 | 0 | 0.24 | 2.7e-06 | 0.007 |
8 | CSGALNACT2 | chondroitin sulfate N-acetylgalactosaminyltransferase 2 | 278270 | 7 | 7 | 3 | 1 | 1 | 5 | 1 | 0 | 0 | 0 | 0.63 | 4.2e-06 | 0.0096 |
9 | TP53 | tumor protein p53 | 212975 | 7 | 7 | 7 | 0 | 1 | 2 | 1 | 2 | 1 | 0 | 0.18 | 6.6e-06 | 0.013 |
10 | CHCHD3 | coiled-coil-helix-coiled-coil-helix domain containing 3 | 110451 | 5 | 5 | 5 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 0.44 | 7.2e-06 | 0.013 |
11 | SETD2 | SET domain containing 2 | 1138298 | 17 | 16 | 17 | 2 | 5 | 1 | 1 | 0 | 10 | 0 | 0.62 | 0.000021 | 0.035 |
12 | ATP1B1 | ATPase, Na+/K+ transporting, beta 1 polypeptide | 156606 | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0.67 | 0.000029 | 0.044 |
13 | SKI | v-ski sarcoma viral oncogene homolog (avian) | 211009 | 6 | 6 | 1 | 1 | 0 | 0 | 6 | 0 | 0 | 0 | 0.24 | 0.000045 | 0.063 |
14 | SAV1 | salvador homolog 1 (Drosophila) | 194642 | 5 | 5 | 5 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0.69 | 0.000084 | 0.11 |
15 | NLRC3 | NLR family, CARD domain containing 3 | 464040 | 9 | 9 | 8 | 1 | 2 | 3 | 4 | 0 | 0 | 0 | 0.19 | 0.0001 | 0.13 |
16 | AGPS | alkylglycerone phosphate synthase | 305060 | 7 | 7 | 7 | 0 | 2 | 1 | 3 | 1 | 0 | 0 | 0.3 | 0.00013 | 0.14 |
17 | HOXD8 | homeobox D8 | 103787 | 4 | 4 | 3 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0.55 | 0.00014 | 0.14 |
18 | IDUA | iduronidase, alpha-L- | 188632 | 5 | 5 | 2 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0.55 | 0.00014 | 0.14 |
19 | TDG | thymine-DNA glycosylase | 211447 | 5 | 5 | 3 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 0.53 | 0.00017 | 0.16 |
20 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 205593 | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0.5 | 0.00018 | 0.16 |
21 | SMARCB1 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 | 196551 | 5 | 5 | 4 | 1 | 0 | 1 | 1 | 0 | 3 | 0 | 0.81 | 0.00018 | 0.16 |
22 | C6orf195 | chromosome 6 open reading frame 195 | 65184 | 5 | 4 | 5 | 0 | 2 | 0 | 0 | 0 | 3 | 0 | 0.34 | 0.00019 | 0.16 |
23 | C1orf146 | chromosome 1 open reading frame 146 | 93424 | 4 | 4 | 4 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0.52 | 0.0002 | 0.16 |
24 | BHMT | betaine-homocysteine methyltransferase | 209882 | 6 | 6 | 6 | 1 | 1 | 0 | 1 | 3 | 1 | 0 | 0.57 | 0.00025 | 0.19 |
25 | FCGR2A | Fc fragment of IgG, low affinity IIa, receptor (CD32) | 164976 | 5 | 5 | 4 | 0 | 2 | 0 | 0 | 2 | 1 | 0 | 0.34 | 0.00034 | 0.25 |
26 | CDC27 | cell division cycle 27 homolog (S. cerevisiae) | 413994 | 7 | 7 | 7 | 0 | 1 | 0 | 2 | 3 | 1 | 0 | 0.18 | 0.00037 | 0.26 |
27 | NFE2L2 | nuclear factor (erythroid-derived 2)-like 2 | 301601 | 6 | 6 | 6 | 0 | 1 | 3 | 0 | 2 | 0 | 0 | 0.35 | 0.00038 | 0.26 |
28 | ACER1 | alkaline ceramidase 1 | 129934 | 4 | 4 | 4 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0.25 | 0.0004 | 0.27 |
29 | SCRN2 | secernin 2 | 221773 | 6 | 6 | 6 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0.56 | 0.00043 | 0.27 |
30 | ANKRD36B | ankyrin repeat domain 36B | 271246 | 5 | 5 | 5 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0.35 | 0.00044 | 0.27 |
31 | SHC2 | SHC (Src homology 2 domain containing) transforming protein 2 | 170770 | 5 | 5 | 5 | 0 | 2 | 1 | 0 | 2 | 0 | 0 | 0.26 | 0.00045 | 0.27 |
32 | BAGE | B melanoma antigen | 15223 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.83 | 0.00047 | 0.27 |
33 | S100A3 | S100 calcium binding protein A3 | 52664 | 3 | 3 | 3 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0.26 | 0.00052 | 0.29 |
34 | PEBP1 | phosphatidylethanolamine binding protein 1 | 78003 | 3 | 3 | 3 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0.42 | 0.00061 | 0.31 |
35 | LGI4 | leucine-rich repeat LGI family, member 4 | 149868 | 4 | 4 | 4 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 0.67 | 0.00061 | 0.31 |
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
---|---|---|---|---|---|---|---|---|---|
1 | MET | met proto-oncogene (hepatocyte growth factor receptor) | 16 | 34 | 7 | 5712 | 27 | 0 | 0 |
2 | NF2 | neurofibromin 2 (merlin) | 12 | 550 | 9 | 92400 | 45 | 6.9e-10 | 1.6e-06 |
3 | TP53 | tumor protein p53 | 7 | 356 | 5 | 59808 | 486 | 9.3e-06 | 0.014 |
4 | FGFR3 | fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) | 6 | 62 | 3 | 10416 | 1469 | 0.000016 | 0.019 |
5 | SMARCB1 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 | 5 | 129 | 3 | 21672 | 14 | 0.00014 | 0.13 |
6 | SMARCA4 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 | 8 | 30 | 2 | 5040 | 3 | 0.00025 | 0.16 |
7 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 5 | 767 | 5 | 128856 | 42 | 0.00034 | 0.16 |
8 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 2 | 52 | 2 | 8736 | 29208 | 0.00075 | 0.16 |
9 | CDCA8 | cell division cycle associated 8 | 1 | 1 | 1 | 168 | 1 | 0.00075 | 0.16 |
10 | FLCN | folliculin | 1 | 1 | 1 | 168 | 1 | 0.00075 | 0.16 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | ARF3(2), CDK2(1), CDK4(1), CDKN1A(1), CDKN2A(2), E2F2(2), MDM2(1), PRB1(2), TP53(7) | 2124020 | 19 | 16 | 19 | 1 | 5 | 2 | 3 | 3 | 5 | 1 | 0.05 | 0.0018 | 1 |
2 | NUCLEOTIDE_GPCRS | ADORA1, ADORA2A, ADORA2B, ADORA3, GPR23, LTB4R, P2RY1, P2RY2, P2RY5, P2RY6 | 8 | ADORA1(2), ADORA2A(3), ADORA3(2), P2RY1(2), P2RY2(1), P2RY6(2) | 1486127 | 12 | 11 | 12 | 1 | 5 | 2 | 3 | 2 | 0 | 0 | 0.045 | 0.02 | 1 | |
3 | HSA00627_1,4_DICHLOROBENZENE_DEGRADATION | Genes involved in 1,4-dichlorobenzene degradation | CMBL | 1 | CMBL(2) | 127344 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.86 | 0.046 | 1 |
4 | RABPATHWAY | Rab family GTPases regulate vesicle transport, endocytosis and exocytosis, and vesicle docking via interactions with the rabphilins. | ACTA1, MEL, RAB11A, RAB1A, RAB2, RAB27A, RAB3A, RAB4A, RAB5A, RAB6A, RAB7, RAB9A | 9 | ACTA1(1), RAB11A(1), RAB1A(1), RAB27A(2), RAB3A(1), RAB6A(1) | 1075847 | 7 | 7 | 7 | 1 | 1 | 0 | 3 | 1 | 2 | 0 | 0.5 | 0.054 | 1 |
5 | HSA00740_RIBOFLAVIN_METABOLISM | Genes involved in riboflavin metabolism | ACP1, ACP2, ACP5, ACP6, ACPP, ACPT, ENPP1, ENPP3, FLAD1, LHPP, MTMR1, MTMR2, MTMR6, PHPT1, RFK, TYR | 16 | ACP2(1), ACP5(1), ACP6(4), ACPP(2), ACPT(1), ENPP1(6), ENPP3(1), FLAD1(1), MTMR2(2), MTMR6(4), PHPT1(1) | 3795599 | 24 | 19 | 22 | 1 | 9 | 1 | 4 | 7 | 3 | 0 | 0.014 | 0.098 | 1 |
6 | ARGININECPATHWAY | Related catabolic pathways process arginine, histidine, glutamine, and proline through glutamate to alpha-ketoglutamate, which feeds into the citric acid cycle. | ALDH4A1, ARG1, GLS, GLUD1, OAT, PRODH | 6 | ALDH4A1(3), ARG1(1), GLS(5), OAT(1), PRODH(1) | 1428662 | 11 | 11 | 11 | 2 | 5 | 0 | 0 | 3 | 3 | 0 | 0.45 | 0.1 | 1 |
7 | BETAOXIDATIONPATHWAY | Beta-Oxidation of Fatty Acids | ACADL, ACADM, ACADS, ACAT1, ECHS1, HADHA | 6 | ACADL(4), HADHA(3) | 1371296 | 7 | 7 | 7 | 0 | 1 | 0 | 2 | 3 | 0 | 1 | 0.19 | 0.14 | 1 |
8 | HSA00730_THIAMINE_METABOLISM | Genes involved in thiamine metabolism | LHPP, MTMR1, MTMR2, MTMR6, NFS1, PHPT1, THTPA, TPK1 | 8 | MTMR2(2), MTMR6(4), NFS1(2), PHPT1(1), THTPA(1), TPK1(1) | 1613515 | 11 | 10 | 10 | 1 | 5 | 2 | 3 | 1 | 0 | 0 | 0.2 | 0.14 | 1 |
9 | REDUCTIVE_CARBOXYLATE_CYCLE_CO2_FIXATION | ACO1, ACO2, FH, IDH1, IDH2, MDH1, MDH2, SDHB, SUCLA2 | 9 | ACO1(1), ACO2(3), FH(2), IDH1(2), IDH2(4), MDH1(1), SDHB(2), SUCLA2(1) | 2250565 | 16 | 15 | 16 | 2 | 8 | 1 | 1 | 1 | 5 | 0 | 0.11 | 0.15 | 1 | |
10 | SA_REG_CASCADE_OF_CYCLIN_EXPR | Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases. | CCNA1, CCNA2, CCND1, CCNE1, CCNE2, CDK2, CDK4, CDKN1B, CDKN2A, E2F1, E2F2, E2F4, PRB1 | 13 | CCNA1(1), CCNE1(2), CCNE2(1), CDK2(1), CDK4(1), CDKN2A(2), E2F2(2), PRB1(2) | 2277484 | 12 | 11 | 12 | 0 | 4 | 0 | 2 | 2 | 3 | 1 | 0.059 | 0.18 | 1 |
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NUCLEOTIDE_GPCRS | ADORA1, ADORA2A, ADORA2B, ADORA3, GPR23, LTB4R, P2RY1, P2RY2, P2RY5, P2RY6 | 8 | ADORA1(2), ADORA2A(3), ADORA3(2), P2RY1(2), P2RY2(1), P2RY6(2) | 1486127 | 12 | 11 | 12 | 1 | 5 | 2 | 3 | 2 | 0 | 0 | 0.045 | 0.02 | 1 | |
2 | HSA00627_1,4_DICHLOROBENZENE_DEGRADATION | Genes involved in 1,4-dichlorobenzene degradation | CMBL | 1 | CMBL(2) | 127344 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.86 | 0.046 | 1 |
3 | RABPATHWAY | Rab family GTPases regulate vesicle transport, endocytosis and exocytosis, and vesicle docking via interactions with the rabphilins. | ACTA1, MEL, RAB11A, RAB1A, RAB2, RAB27A, RAB3A, RAB4A, RAB5A, RAB6A, RAB7, RAB9A | 9 | ACTA1(1), RAB11A(1), RAB1A(1), RAB27A(2), RAB3A(1), RAB6A(1) | 1075847 | 7 | 7 | 7 | 1 | 1 | 0 | 3 | 1 | 2 | 0 | 0.5 | 0.054 | 1 |
4 | HSA00740_RIBOFLAVIN_METABOLISM | Genes involved in riboflavin metabolism | ACP1, ACP2, ACP5, ACP6, ACPP, ACPT, ENPP1, ENPP3, FLAD1, LHPP, MTMR1, MTMR2, MTMR6, PHPT1, RFK, TYR | 16 | ACP2(1), ACP5(1), ACP6(4), ACPP(2), ACPT(1), ENPP1(6), ENPP3(1), FLAD1(1), MTMR2(2), MTMR6(4), PHPT1(1) | 3795599 | 24 | 19 | 22 | 1 | 9 | 1 | 4 | 7 | 3 | 0 | 0.014 | 0.098 | 1 |
5 | ARGININECPATHWAY | Related catabolic pathways process arginine, histidine, glutamine, and proline through glutamate to alpha-ketoglutamate, which feeds into the citric acid cycle. | ALDH4A1, ARG1, GLS, GLUD1, OAT, PRODH | 6 | ALDH4A1(3), ARG1(1), GLS(5), OAT(1), PRODH(1) | 1428662 | 11 | 11 | 11 | 2 | 5 | 0 | 0 | 3 | 3 | 0 | 0.45 | 0.1 | 1 |
6 | BETAOXIDATIONPATHWAY | Beta-Oxidation of Fatty Acids | ACADL, ACADM, ACADS, ACAT1, ECHS1, HADHA | 6 | ACADL(4), HADHA(3) | 1371296 | 7 | 7 | 7 | 0 | 1 | 0 | 2 | 3 | 0 | 1 | 0.19 | 0.14 | 1 |
7 | HSA00730_THIAMINE_METABOLISM | Genes involved in thiamine metabolism | LHPP, MTMR1, MTMR2, MTMR6, NFS1, PHPT1, THTPA, TPK1 | 8 | MTMR2(2), MTMR6(4), NFS1(2), PHPT1(1), THTPA(1), TPK1(1) | 1613515 | 11 | 10 | 10 | 1 | 5 | 2 | 3 | 1 | 0 | 0 | 0.2 | 0.14 | 1 |
8 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 14 | ARF3(2), CDK2(1), CDK4(1), CDKN1A(1), CDKN2A(2), E2F2(2), MDM2(1), PRB1(2) | 1911045 | 12 | 10 | 12 | 1 | 4 | 0 | 2 | 1 | 4 | 1 | 0.2 | 0.15 | 1 |
9 | REDUCTIVE_CARBOXYLATE_CYCLE_CO2_FIXATION | ACO1, ACO2, FH, IDH1, IDH2, MDH1, MDH2, SDHB, SUCLA2 | 9 | ACO1(1), ACO2(3), FH(2), IDH1(2), IDH2(4), MDH1(1), SDHB(2), SUCLA2(1) | 2250565 | 16 | 15 | 16 | 2 | 8 | 1 | 1 | 1 | 5 | 0 | 0.11 | 0.15 | 1 | |
10 | SA_REG_CASCADE_OF_CYCLIN_EXPR | Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases. | CCNA1, CCNA2, CCND1, CCNE1, CCNE2, CDK2, CDK4, CDKN1B, CDKN2A, E2F1, E2F2, E2F4, PRB1 | 13 | CCNA1(1), CCNE1(2), CCNE2(1), CDK2(1), CDK4(1), CDKN2A(2), E2F2(2), PRB1(2) | 2277484 | 12 | 11 | 12 | 0 | 4 | 0 | 2 | 2 | 3 | 1 | 0.059 | 0.18 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.